Division of Cardiology, Department of Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
J Intern Med. 2012 May;271(5):451-62. doi: 10.1111/j.1365-2796.2011.02479.x. Epub 2011 Nov 30.
To explore the diagnostic accuracies of anti-apolipoproteinA-1 (anti-ApoA-1) IgG and anti-phosphorylcholine (anti-PC) IgM alone, expressed as a ratio (anti-ApoA-1 IgG/anti-PC IgM), and combined with the Thrombolysis In Myocardial Infarction (TIMI) score for non-ST-segment elevation myocardial infarction (NSTEMI) (NSTEMI-TIMI score) to create a new diagnostic algorithm - the Clinical Autoantibody Ratio (CABR) score - for the diagnosis of NSTEMI and subsequent cardiac troponin I (cTnI) elevation in patients with acute chest pain (ACP).
In this single-centre prospective study, 138 patients presented at the emergency department with ACP without ST-segment elevation myocardial infarction. Anti-ApoA-1 IgG and anti-PC IgM were assessed by enzyme-linked immunosorbent assay on admission. Post hoc determination of the CABR score cut-off was performed by receiver operating characteristics analyses.
The adjudicated final diagnosis was NSTEMI in 17% (24/138) of patients. Both autoantibodies alone were found to be significant predictors of NSTEMI diagnosis, but the CABR score had the best diagnostic accuracy [area under the curve (AUC): 0.88; 95% confidence interval (CI): 0.82-0.95]. At the optimal cut-off of 3.3, the CABR score negative predictive value (NPV) was 97% (95% CI: 90-99). Logistic regression analysis showed that a CABR score >3.3 increased the risk of subsequent NSTEMI diagnosis 19-fold (odds ratio: 18.7; 95% CI: 5.2-67.3). For subsequent cTnI positivity, only anti-ApoA-1 IgG and CABR score displayed adequate predictive accuracies with AUCs of 0.80 (95% CI: 0.68-0.91) and 0.82 (95% CI: 0.70-0.94), respectively; the NPVs were 95% (95% CI: 90-98) and 99% (95% CI: 94-100), respectively.
The CABR score, derived from adding the anti-ApoA-1 IgG/anti-PC IgM ratio to the NSTEMI-TIMI score, could be a useful measure to rule out NSTEMI in patients presenting with ACP at the emergency department without electrocardiographic changes.
探讨抗载脂蛋白 A-1(anti-ApoA-1)IgG 和抗磷酸胆碱(anti-PC)IgM 单独以及与非 ST 段抬高型心肌梗死(NSTEMI)的 Thrombolysis In Myocardial Infarction(TIMI)评分(NSTEMI-TIMI 评分)相结合的诊断准确性,以创建一种新的诊断算法-临床自身抗体比值(CABR)评分,用于诊断急性胸痛(ACP)患者的 NSTEMI 及随后的心肌肌钙蛋白 I(cTnI)升高。
在这项单中心前瞻性研究中,138 名因 ACP 而在急诊科就诊的患者无 ST 段抬高型心肌梗死。入院时通过酶联免疫吸附试验测定抗 ApoA-1 IgG 和抗 PC IgM。通过受试者工作特征分析事后确定 CABR 评分截断值。
17%(24/138)的患者最终诊断为 NSTEMI。两种自身抗体单独均为 NSTEMI 诊断的重要预测指标,但 CABR 评分具有最佳的诊断准确性[曲线下面积(AUC):0.88;95%置信区间(CI):0.82-0.95]。在最佳截断值为 3.3 时,CABR 评分的阴性预测值(NPV)为 97%(95%CI:90-99)。逻辑回归分析表明,CABR 评分>3.3 使随后 NSTEMI 诊断的风险增加 19 倍(优势比:18.7;95%CI:5.2-67.3)。对于随后的 cTnI 阳性,只有抗 ApoA-1 IgG 和 CABR 评分具有足够的预测准确性,AUC 分别为 0.80(95%CI:0.68-0.91)和 0.82(95%CI:0.70-0.94);NPV 分别为 95%(95%CI:90-98)和 99%(95%CI:94-100)。
从添加抗 ApoA-1 IgG/抗 PC IgM 比值到 NSTEMI-TIMI 评分得出的 CABR 评分,可以成为一种有用的方法,用于排除急诊科因心电图改变而出现 ACP 的患者发生 NSTEMI。